RICHARD J BRAM, M.D.
Osteopathic Medicine at 1 St, Rochester, MN
License number
Minnesota 41147
Category
Osteopathic Medicine
Type
Hematology & Oncology
Address
Address
200 1St St SW, Rochester, MN 55905
Phone
(507) 284-2511
Organization information
See more information about RICHARD J BRAM at bizstanding.comMayo Clinic - Richard J Bram MD
200 1 St SW #W4, Rochester, MN 55905
Categories:
Physicians & Surgeons
Phone:
(507) 266-0368 (Phone)
Professional information
Dr. Richard J Bram, Rochester MN - MD (Doctor of Medicine)
Specialties:
Oncology, Pediatric Hematology & Oncology
Address:
Mayo Clinic
200 1St St SW, Rochester 55905
(507) 284-2511 (Phone)
200 1St St SW, Rochester 55905
(507) 284-2511 (Phone)
Certifications:
Pediatric Oncology & Pediatric Hematology, 2002, Pediatrics, 1993
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Stanford University School Of Medicine
Graduated: 1987
Stanford University Hospital
Stanford University School Of Medicine
Graduated: 1987
Stanford University Hospital
Richard J Bram, Rochester MN
Specialties:
Pediatric Hematologist / Oncologist
Address:
200 1St St Sw, Rochester, MN 55905
Education:
Stanford University, School of Medicine - Doctor of Medicine
Board certifications:
American Board of Pediatrics Sub-certificate in Pediatric Hematology/Oncology (Pediatrics)
Lymphocyte Surface Receptor That Binds Caml And Methods Of Use Thereof
US Patent:
7355005, Apr 8, 2008
Filed:
Dec 23, 2005
Appl. No.:
11/318156
Inventors:
Richard J. Bram - Rochester MN, US
Gotz Von Bulow - Carmel IN, US
Gotz Von Bulow - Carmel IN, US
Assignee:
St. Jude Children's Research Hospital - Memphis TN
International Classification:
C07K 14/435, A61K 38/17
US Classification:
530350, 530300, 514 12
Abstract:
A novel lymphocyte receptor protein, its DNA sequence, and its role in the calcium activation pathway is described. The protein, or genetically engineered constructs encoding it, is shown to increase lymphocyte response, and to identify ligands of the protein receptor. Antibodies to the proteins of the invention are generated for diagnostic therapeutics. The protein and DNA can also be used for diagnostic purposes and for identifying agents for modulating the calcium induced activation pathway. A particular advantage of the present invention is that it provides lymphocyte activation of receptor found on all B cells, but only on a subset of T cells. The receptor can thus be targeted to specifically regulate B cell responses without affecting mature T cell activity. Such targeting specificity is always advantageous, particularly where an increase or decrease of antibody production is desired, e. g. , during an infection (increase) or to avoid immune complex deposition complications (rheumatoid arthritis, glomerulonephritis, and other auto immune conditions).
Lymphocyte Surface Receptor That Binds Caml And Methods Of Use Thereof
US Patent:
2005018, Aug 18, 2005
Filed:
Mar 14, 2005
Appl. No.:
11/079418
Inventors:
Richard Bram - Rochester MN, US
Gotz Von Bulow - Carmel IN, US
Gotz Von Bulow - Carmel IN, US
Assignee:
St. Jude Children's Research Hospital - Memphis TN
International Classification:
A01K067/027, C12N005/06
US Classification:
800018000, 435354000
Abstract:
A novel lymphocyte receptor protein, its DNA sequence, and its role in the calcium activation pathway is described. The protein, or genetically engineered constructs encoding it, is shown to increase lymphocyte response, and to identify ligands of the protein receptor. Antibodies to the proteins of the invention are generated for diagnostic therapeutics. The protein and DNA can also be used for diagnostic purposes and for identifying agents for modulating the calcium induced activation pathway. A particular advantage of the present invention is that it provides lymphocyte activation of receptor found on all B cells, but only on a subset of T cells. The receptor can thus be targeted to specifically regulate B cell responses without affecting mature T cell activity. Such targeting specificity is always advantageous, particularly where an increase or decrease of antibody production is desired, e.g., during an infection (increase) or to avoid immune complex deposition complications (rheumatoid arthritis, glomerulonephritis, and other auto immune conditions).
Lymphocyte Surface Receptor That Binds Caml And Methods Of Use Thereof
US Patent:
2009022, Sep 10, 2009
Filed:
Feb 7, 2008
Appl. No.:
12/027720
Inventors:
Richard J. Bram - Rochester MN, US
Gotz Von Bulow - Carmel IN, US
Gotz Von Bulow - Carmel IN, US
Assignee:
St. Jude Children's Research Hospital - Memphis TN
International Classification:
A61K 39/00, A61P 35/00
US Classification:
4241851
Abstract:
A novel lymphocyte receptor protein, its DNA sequence, and its role in the calcium activation pathway is described. The protein, or genetically engineered constructs encoding it, is shown to increase lymphocyte response, and to identify ligands of the protein receptor. Antibodies to the proteins of the invention are generated for diagnostic therapeutics. The protein and DNA can also be used for diagnostic purposes and for identifying agents for modulating the calcium induced activation pathway. A particular advantage of the present invention is that it provides lymphocyte activation of receptor found on all B cells, but only on a subset of T cells. The receptor can thus be targeted to specifically regulate B cell responses without affecting mature T cell activity. Such targeting specificity is always advantageous, particularly where an increase or decrease of antibody production is desired, e.g., during an infection (increase) or to avoid immune complex deposition complications (rheumatoid arthritis, glomerulonephritis, and other auto immune conditions).